Liver damage following hepatitis B virus (HBV) infection may be due to the action of retinoids as modulators of viral replication. The reduced rate of survival of liver grafts in patients with HBV infection could also be due to the continued presence of the virus, stimulated by retinoids in the graft tissue. Subject to obtaining empirical support for this hypothesis, the use of retinoid-blocking agents could be explored to reduce the risk of liver damage in HBV infection and to enhance the survival of liver grafts. Continued use of such agents may need to be used in conjunction with anti-viral modalities such as HBV hyperimmune globulin and lamivudine to prevent recurrent liver damage and to increase the long-term viability of the graft.
OnishiS, SaibaraT, ItoK. Hepatitis B surface antigen specific cytotoxic T lymphocyte activity in hepatitis B virus infection. Gastroenterol Jpn20: 330337, 1985.
8.
BertolettiA, FerrariC, FiaccadoriF, PennaA, MargolskeeR, SchlichtHJ, FowlerP, GuilhotS, ChisariFV. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A88: 1044510449, 1991.
9.
MarinosG, RossolS, CarucciP, WongPY, DonaldsonP, HussainMJ, VerganiD, PortmannBC, WilliamsR, NaoumovNV. Immunopathogenesis of hepatitis B virus recurrence after liver transplantation. Transplantation69: 559568, 2000.
10.
ThomasHC, KarayiannisP, BrookG. Treatment of hepatitis B virus infection with interferon: Factors predicting response to interferon. J Hepatol13: S4S7, 1991.
11.
FrancoA, BarnabaV, LevreroM, RubertiG, Van DykeA, BonavitaMS, BalsanoF J. Effect of 28 consecutive days lymphoblastoid interferon (alpha-IFN) administration on hepatitis B virus related chronic liver disease. Hepatology3: S239S243, 1986.
12.
WrightTL, LauJYN. Clinical aspects of hepatitis B virus infection. Lancet342: 13401344, 1993.
13.
KeeffeEB. End-stage liver disease and liver transplantation: Role of lemivudine therapy in patients with chronic hepatitis B. J Med Virol61: 403408, 2000.
14.
LauJYN, BainVG, DaviesSE, O'gradyJG, AlbertiA, AlexanderGJM, WilliamsR. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology102: 956962, 1992.
15.
ChisariFB, KlopchinK, MoriyamaT, PasquinelliC, DunsfordHA, SellS, PinkertCA, BrinsterRL, PalmiterRD. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell59: 11451156, 1989.
16.
RoingeardP, Romet-LemonneJL, LeturcqD, GondeauA, EssexM. Hepatitis B virus core antigen (HBcAg) accumulation in an HVB non-producer clone of HepG2-transfected cells is associated with cytopathic effect. Virology179: 113120, 1990.
17.
BlomhoffR, GreenMH, BergT, NorumKR. Transport and storage of vitamin A. Science250: 399404, 1990.
18.
HoffmanC, EicheleG. Retinoids in development. In: SpornMB, RobertsAB, GoodmanDS, Eds. The Retinoids: Biology, Chemistry, and Medicine. New York: Raven Press, pp 387441, 1994.
19.
JettenAM. Modulation of cell growth and differentiation by retinoids and their mechanisms of action. In: MeyskensFL, PrasadKN, Eds. Modulation and Mediation of Cancer by Vitamins. Basel: S. Karger, pp 177186, 1983.
20.
GangulyJ. The Biochemistry of Vitamin A. Boca Raton, FL: CRC Press, 1989.
21.
CarlbergC. Lipid soluble vitamins in gene expression. Biofactors10: 9197, 1999.
GoodmanDS. Vitamin A and retinoids in health and disease. N Engl J Med310: 10231031, 1984.
24.
SmithFR, GoodmanDS. Vitamin A transport and human vitamin A toxicity. N Engl J Med294: 805808, 1986.
25.
OlsonJA. Vitamin A. In: ZieglerEE, FilerLJJr., Eds. Present Knowledge in Nutrition, 7th edition. Washington, DC: International Life Sciences Institute Press, pp 109119, 1996.
26.
KeilsonB, UnderwoodBA, LoerchJD. Effects of retinoic acid on the mobilization of vitamin A from the liver in rats. J Nutr79: 787795, 1979.
27.
BaruaAB, DuitsmanPK, KosticD, BaruaM, OlsonJA. Reduction of serum retinol levels following a single oral dose of all-trans-retinoic acid in humans. Int J Vitam Nutr Res67: 423426, 1996.
28.
SmithFR, GoodmanDS. The effects of diseases of liver, thyroid, and kidneys on the transport of vitamin A in human plasma. J Clin Invest50: 24262436, 1971.
29.
UnderwoodBA. Vitamin A in animal and human nutrition. In: SpornMB, RobertsAB, GoodmanDS, Eds. The Retinoids, Volume 1. New York: Academic Press, pp 281392, 1984.
30.
MooreT. Vitamin A. New York: Elsevier North Holland, Inc., pp 430431, 1957.
31.
MezeyELiver disease, and protein needs. Annu Rev Nutr2: 2150, 1982.
32.
LieberCS, LeoMA. Interaction of alcohol and nutritional factors with hepatic fibrosis. Prog Liver Dis8: 253272, 1986.
33.
De LucaLM, CreekKE. Vitamin A and the liver. Prog Liver Dis8: 8198, 1986.
34.
RussellRM, BoyerJL, BagheriSA, HrubanZ. Hepatic injury from chronic hypervitaminosis A resulting in portal hypertension and ascites. N Engl J Med291: 435440, 1974.
35.
LiD, FriedmanSL. Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy. J Gastroenterol Hepatol17: 618633, 1999.
36.
OkunoM, SatoT, KitamotoT, ImaiS, KawadaN, SuzukiY, YoshimuraH, MoriwakiH, OnukiK, MasushigeS, MutoY, FriedmanSL, KatoS, KojimaS. Increased 9, 13-di-cis-retinoic acid in rat hepatic fibrosis: Implication for a potential link between retinoid loss and TGF-beta mediated fibrogenesis in vivo. J Hepatol30: 10731080, 1999.
37.
HuanB, SiddiquiA. Regulation of hepatitis B virus gene expression. J Hepatol17(Suppl 3):S20S23, 1993.
38.
HuanB, SiddiquiA. Retinoid X receptor RXR alpha binds to and trans-activates the hepatitis B virus enhancer. Proc Natl Acad Sci U S A89: 90599063, 1992.
39.
GarciaAD, OstapchukP, HearingP. Functional interaction of nuclear factors EF-C, HN-4, and RXR alpha with hepatitis B virus enhancer I. J Virol67: 39403950, 1993.
40.
HsuSL, LinYF, ChouCK. Retinoic acid biphasically regulates the gene expression of hepatitis B virus surface antigen in human hepatoma Hep 3B cells. J Biol Chem268: 2309323097, 1993.
41.
YuX, MertzJE. Differential regulation of the pre-C and pregenomic promoters of human hepatitis B virus by members of the nuclear receptor superfamily. J Virol71: 93669374, 1997.
42.
BeasleyRP, HwangLY, LinCC, ChienCS. Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22,707 men in Taiwan. Lancet2: 11291133, 1981.
43.
SzmunessW. Hepatocellular carcinoma and the hepatitis B virus: Evidence for a causal association. Prog Med Virol24: 4069, 1978.
44.
BenbrookD, LernhardtE, PfahlM. A new retinoic acid receptor identified from a hepatocellular carcinoma. Nature333: 669672, 1988.
45.
DejeanA, de TheH. Hepatitis B virus as an insertional mutagene in a human hepatocellular carcinoma. Mol Biol Med7: 213222, 1990.
46.
Di BisceglieAM. Hepatocellular carcinoma: molecular biology of its growth and relationship to hepatitis B virus infection. Med Clin North Am73: 985997, 1989.
47.
HamadaT, KumashiroR, KogaY, HinoT, FuruderaS, SakisakaS, SataM, TanikawaK, TaguchiJ, KageM. Fatal acute hepatitis B virus infection while receiving immunosuppressants after renal transplantation. Intern Med32: 547551, 1993.
48.
MalikAH, LeeWM. Chronic hepatitis B virus infection: Treatment strategies for the next millennium. Ann Intern Med132: 723731, 2000.
49.
ChanTM, WuPC, LiFK, LaiCL, ChengIK, LaiKN. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology115: 177181, 1998.
50.
Al FaraidyK, YoshidaEM, DavisJE, VartanianRK, AndersonFH, SteinbrecherUP. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation64: 926928, 1997.
51.
MutimerD, PillayD, ShieldsP, CaneP, RatcliffeD, MartinB, BuchanS, BoxallL, O'donnellK, ShawJ, HubscherS, EliasE. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut46: 107113, 2000.
52.
TomaS, IsnardiL, RaffoP, RiccardiL, DastoliG, ApfelC, LeMotteP, BollagW. RARalpha antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines. Int J Cancer78: 8694, 1998.
53.
StandevenAM, JohnsonAT, EscobarM, ChandraratnaRA. Specific antagonist of retinoid toxicity in mice. Toxicol Appl Pharmacol138: 169175, 1996.
SafranAB, HaliquaB, RothA, SauratJ-A. Ocular side effects of oral treatment with retinoids. In: SauratJ-A, Ed. Retinoids: Ten Years On. Basel: S. Karger, pp 315326, 1990.
56.
DiGiovannaJJ, SollittoRB, AbanganDL, SteinbergSM, ReynoldsJC. Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol131: 12631267, 1995.
